PREDICTORS OF EARLY DISCONTINUATION OF INTERFERON-FREE DIRECT ANTIVIRAL AGENTS IN PATIENTS WITH HCV AND ADVANCED FIBROSIS- RESULTS OF A REAL-LIFE COHORT
Author(s)
Miotto N, Mendes LC, Zanaga LP, Goncales ES, Lazarini MS, Pedro MN, Goncales Jr FL, Stucchi RS, Vigani AG, Vigani AG
UNICAMP, Campinas- SP, Brazil
Presentation Documents
OBJECTIVES:: To determinate risk factors for premature treatment discontinuation among patients infected with HCV with advanced fibrosis treated with IFN-free direct antiviral agents (DAA)-based therapy METHODS:: We included all patients with chronic HCV infection and advanced fibrosis who initiated treatment with IFN-free DAA therapy at an university hospital from December 2015 through June 2016. We prospectively collected data from medical records using standardized questionnaires and evaluated them using EpiInfo 7.1.2.0. Primary outcome was treatment interruption and factors associated. RESULTS:: Of total, 214 patients were included in this study, 180 patients treated with sofosbuvir(SOF) + daclatasvir ± ribavirin(RBV), 31 received SOF + simeprevir ± RBV, and 3 treated with SOF+RBV. Treatment discontinuation rate was 8.9% (19), and cirrhotic decompensation was the main reason (8; 42.1%). Among patients with Child B or C cirrhosis (31), 10 (32.2%) prematurely interrupted treatment. Risk factors for treatment discontinuation in univariate analysis were higher age (p
Conference/Value in Health Info
2017-09, ISPOR Latin America 2017, Sao Paulo, Brazil
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PIN3
Topic
Epidemiology & Public Health
Topic Subcategory
Safety & Pharmacoepidemiology
Disease
Infectious Disease (non-vaccine)
Your browser is out-of-date
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now